JP2007515426A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515426A5
JP2007515426A5 JP2006545577A JP2006545577A JP2007515426A5 JP 2007515426 A5 JP2007515426 A5 JP 2007515426A5 JP 2006545577 A JP2006545577 A JP 2006545577A JP 2006545577 A JP2006545577 A JP 2006545577A JP 2007515426 A5 JP2007515426 A5 JP 2007515426A5
Authority
JP
Japan
Prior art keywords
composition
pervalanol
use according
salts
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042930 external-priority patent/WO2005063252A1/en
Publication of JP2007515426A publication Critical patent/JP2007515426A/ja
Publication of JP2007515426A5 publication Critical patent/JP2007515426A5/ja
Pending legal-status Critical Current

Links

JP2006545577A 2003-12-22 2004-12-21 緑内障の処置のための短い形態のc−Maf転写因子アンタゴニストとしてのcdk2アンタゴニスト Pending JP2007515426A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53180103P 2003-12-22 2003-12-22
PCT/US2004/042930 WO2005063252A1 (en) 2003-12-22 2004-12-21 Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma

Publications (2)

Publication Number Publication Date
JP2007515426A JP2007515426A (ja) 2007-06-14
JP2007515426A5 true JP2007515426A5 (https=) 2007-12-06

Family

ID=34738702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545577A Pending JP2007515426A (ja) 2003-12-22 2004-12-21 緑内障の処置のための短い形態のc−Maf転写因子アンタゴニストとしてのcdk2アンタゴニスト

Country Status (15)

Country Link
US (1) US20050159432A1 (https=)
EP (1) EP1696928A1 (https=)
JP (1) JP2007515426A (https=)
KR (1) KR20060110301A (https=)
CN (1) CN1886138A (https=)
AR (1) AR046728A1 (https=)
AU (1) AU2004308938B2 (https=)
BR (1) BRPI0418033A (https=)
CA (1) CA2548035A1 (https=)
MX (1) MXPA06007062A (https=)
RU (1) RU2370267C2 (https=)
TW (1) TW200526224A (https=)
UY (1) UY28660A1 (https=)
WO (1) WO2005063252A1 (https=)
ZA (1) ZA200604576B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1696958T3 (pl) * 2003-12-22 2007-08-31 Alcon Inc Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej
EP1696926A1 (en) * 2003-12-22 2006-09-06 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
WO2008063378A2 (en) 2006-11-01 2008-05-29 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびinsituハイブリダーゼーションのためのポリマー担体
WO2009149013A2 (en) 2008-06-05 2009-12-10 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質p160
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
PT868186E (pt) * 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
ATE247090T1 (de) * 1996-02-02 2003-08-15 Hidaka Hiroyoshi Dr Isochinolinderivate und arzneimittel
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
NZ513800A (en) * 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
EP1307462A2 (en) * 2000-08-09 2003-05-07 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
MXPA05002493A (es) * 2002-09-05 2005-05-27 Neurosearch As Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2007515426A5 (https=)
RU2006126638A (ru) АНТАГОНИСТЫ cdk2 В КАЧЕСТВЕ АНТАГОНИСТОВ КОРОТКОЙ ФОРМЫ ФАКТОРА ТРАНСКРИПЦИИ c-Maf ДЛЯ ЛЕЧЕНИЯ ГЛАУКОМЫ
JP2010536849A5 (https=)
JP2007512371A5 (https=)
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
JP2006528699A5 (https=)
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
WO2008002245A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
NO20065878L (no) Terapeutiske forbindelser
JP2008110970A5 (https=)
WO2008027584A3 (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
JP2007515423A5 (https=)
WO2009050198A3 (en) Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
JP2005538121A5 (ja) 多重遅延放出抗ウイルス物質産物、その使用法と製剤
CA2671954A1 (en) Methods for treating or preventing symptoms of hormonal variations
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
GT200900089A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
JP2008533142A (ja) α7ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
JP2019514990A5 (https=)
CA2557850A1 (en) Methods of treatment using eszopiclone
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
CA2527703A1 (en) New use of staurosporine derivatives
JP2012508239A5 (https=)